These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38597214)

  • 21. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L
    JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin.
    Haass-Koffler CL; Goodyear K; Zywiak WH; Magill M; Eltinge SE; Wallace PM; Long VM; Jayaram-Lindström N; Swift RM; Kenna GA; Leggio L
    Drug Alcohol Depend; 2017 Aug; 177():23-28. PubMed ID: 28551590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.
    Milivojevic V; Angarita GA; Hermes G; Sinha R; Fox HC
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1488-1496. PubMed ID: 32449942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
    Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
    Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans.
    Raskind MA; Peskind ER; Chow B; Harris C; Davis-Karim A; Holmes HA; Hart KL; McFall M; Mellman TA; Reist C; Romesser J; Rosenheck R; Shih MC; Stein MB; Swift R; Gleason T; Lu Y; Huang GD
    N Engl J Med; 2018 Feb; 378(6):507-517. PubMed ID: 29414272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A double blind placebo controlled randomized clinical trial of the efficacy and safety of pregabalin in induction of remission in patients with alcohol dependence].
    Krupitsky EM; Rybakova KV; Skurat EP; Semenova NV; Neznanov NG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(1):33-43. PubMed ID: 32105267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
    Froehlich JC; Hausauer BJ; Rasmussen DD
    Alcohol Clin Exp Res; 2013 Oct; 37(10):1763-70. PubMed ID: 23875623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.
    Miyata H; Takahashi M; Murai Y; Tsuneyoshi K; Hayashi T; Meulien D; Sørensen P; Higuchi S
    Psychiatry Clin Neurosci; 2019 Nov; 73(11):697-706. PubMed ID: 31298784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
    Rasmussen DD; Kincaid CL; Froehlich JC
    Alcohol Clin Exp Res; 2015 Sep; 39(9):1832-41. PubMed ID: 26260061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.
    Ryan ML; Falk DE; Fertig JB; Rendenbach-Mueller B; Katz DA; Tracy KA; Strain EC; Dunn KE; Kampman K; Mahoney E; Ciraulo DA; Sickles-Colaneri L; Ait-Daoud N; Johnson BA; Ransom J; Scott C; Koob GF; Litten RZ
    Neuropsychopharmacology; 2017 Apr; 42(5):1012-1023. PubMed ID: 27658483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled pilot trial of prazosin for prophylaxis of posttraumatic headaches in active-duty service members and veterans.
    Mayer CL; Savage PJ; Engle CK; Groh SS; Shofer JB; Hargrove AM; Williams TJ; Poupore EL; Hart KL; Riechers RG; Ruff RL; Peskind ER; Raskind MA
    Headache; 2023 Jun; 63(6):751-762. PubMed ID: 37313689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled, multicentre trial on the efficacy of varenicline and bupropion in combination and alone for treatment of alcohol use disorder: Protocol for the COMB study.
    de Bejczy A; Lidö H; Söderpalm B
    PLoS One; 2024; 19(1):e0296118. PubMed ID: 38206930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early treatment response in alcohol dependence with extended-release naltrexone.
    Ciraulo DA; Dong Q; Silverman BL; Gastfriend DR; Pettinati HM
    J Clin Psychiatry; 2008 Feb; 69(2):190-5. PubMed ID: 18348601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder.
    Wilcox CE; Adinoff B; Clifford J; Ling J; Witkiewitz K; Mayer AR; Boggs KM; Eck M; Bogenschutz M
    Neuroimage Clin; 2020; 26():102162. PubMed ID: 32037283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
    Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
    JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.